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Calponin, a 35 kDa actin-binding protein, was shown to be a normal component of 'native' thin filaments prepared from sheep aorta. Actin, 
tropomyosin, caldesmon and calponin were present in molar ratios 14 : 2 : 1 : 0.9. Calponin was isolated from thin filaments in yield 0.5 rag/100 
mg thin filament protein. Calponin inhibited actomyosin ATPase up to 85%, half maximal at 0.2 calponin/actin. Inhibition did not depend on 
tropomyosin. Ca z• or Ca -'+.calmodulin, Caldesmon inhibited actomyosin with a I 0-fold greater potency than calponin in the presence of tropomyo- 
sin and inhition could be reversed by Ca".calmodulin under certain conditions. Calponin had no effect on caldesmon inhibition or the reversal 
of inhibition. 
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I. INTRODUCTION 
Smooth muscle cells contain anumber of actin binding 
proteins, which may be broadly classified into those that 
are associated with the cytoskeletal domain (e.g. c~-acti- 
nin, filamin) and those which are associated with the 
contractile actomyosin domain, such as caldesmon [1,2]. 
Calponin is a recently discovered actin binding protein, 
present in all smooth muscle cells, which can also bind 
tropomyosin, Ca ~'+, and Ca=+.calmodulin [3-5]. 
In my laboratory we have developed a procedure for 
the preparation of native thin filaments from any 
smooth muscle and have made a detailed study of thin 
filaments from sheep aorta [6.7]. The thin filaments ac- 
tivate myosin MgATPase activity in a Ca=+-sensitive 
manner and are primarily composed of actin, tropo- 
myosin and caldesmon [8]. It has been noted that some 
preparations of thin filaments from chicken gizzard 
contained calponin [9]. Nishida et al. [10] reported that 
gizzard thin filaments prepared by the Marston and 
Smith technique [7] do not contain calponin, but cal- 
ponin-containing filaments were obtained by a modified 
procedure. If calponin is normally present in thin fila- 
ment preparations then it might be involved in their 
Ca=+-dependent regulation of actomyosin MgATPase 
activity [4.5,9,1 i ]. 
In this study, I have used urea/SDS gel electrophore- 
sis to identify and quantitate calponin in preparations 
of sleep aorta thin filaments. Calponin was then isolated 
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from the thin filaments under mild conditions and its 
regulatory properties were studied. It was found that 
calponin was present in thin filaments at approximately 
the same molar proportion as caldesmon, and that it 
could inhibit actomyosin MgATPase activity; however 
these properties did not support suggestions that it has 
a regulatory function [4,5,9,10]. 
2. MATERIALS AND METHODS 
2. I. Preparation of proteins 
Native thin filaments, tropomyosin and skeletal muscle myosin were 
rrepared from sheep aorta by standard methods [7,12]. F-actin, calpo- 
nin and caldesmon were isolated from native thin filaments. Thin 
filaments, dissolved in 0.8 M KCI, 10 m~,l Tris, pH 8.0, were centrifu- 
ged tot I h at 250 000 x g. The pellet contained pure f-actin and the 
supernatant contained primarily caldesmon, calponin and tropomyo- 
sin (Fig. I B) [13]. Crude calponin was precipitated from the superna- 
rant with 30% saturated ammonium sulphate. The pellet was dissolved 
and dialysed in 0.3 M KCI. 20 mM Tris. pH 7.5, I mM dithiothreitol. 
Residual actin was removed by centrifugation (15 min in a Beckman 
Airfuge). Final purification was by FPLC gel filtration on a superose 
6 column. The yield of pure calponin (Fig. I B) was about 0.5 mg per 
100 mg of thin filament protein. Caldesmon was isolated from a 
30-50% ammonium sulphate fraction of the high speed supernatant 
using standard procedures [13]. 
2.2. As.ray qf protei,s 
Protein concentration was determined by the Lowry method based 
on molccular masses of 42 kOa for actin, 35 kDa for calponin [5] and 
87 kDa for caldesmon [14]. ATPase activity was measured with an 
actomyosin made up of 0.5 mg/ml aorta actin and 0.125 mg/ml skeletal 
muscle myosin [15] in 50 or 90 mM KCI, l0 mM sodium azidc, 5 mM 
MgCb, I mM dithiothreitol. 5 mM PIPES.K:. pH 7.1, at 28 or 37"C. 
Samples (159,ul) were incubated for l0 rain: the reaction was initiated 
by adding MgATP to 2 raM, and terminated with 0.5 ml 5% tri- 
chloroacetic acid. The quantity of P, released was assayed as 
previously described [7,15]. 
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Fig. 1. Uroa/SDS gel electrophoresis of aorta thin filaments and calponin. 20 gtg samples of protein were loaded onto 8% polyacrylamide/0.1% 
SDS/8 M urea/10 mM sodium Phosphate, pH 7.0, slab gels and separated byelectrophoresis for 3.5 h at 60 V in running buffer (100 mM sodium 
Phosphate, pH 7.0/0.1% SDS. Staining was in 0.2% PAGE blue 83 (Merck). (At (1-5) Sheep aorta thin filament preparations, (6)pure tropomyosin. 
In this gel system tropomyosin migrates anomalously with an apparent mass of 55 kDa. A band migrating at35 kDa was detected in all thin filament 
preparations. Identified bands are CD. caldesmon; Tin, tropomyosin: A, actin; CP, 35 kDa protein (calponin). (B) Steps in the purification of 
¢alponin from thin filaments. (1) Supernatant following ultracentrifugation of thin filaments in 0.8 M KCI; (2) 0-30% ammonium sulphate fraction 
from supernatant, major components are actin and calponin; (3) ealponin, purified on superose 6 column; (4) tropomyosin: (5) caldesmon. 
3. RESULTS 
3. I. Native sheep aorta thin filaments contain calpon#l 
Calponin could not be distinguished by SDS-gel elec- 
trophoresis of sheep aorta thin filaments because of its 
proximity to the tropomyosin band. However on 8% 
polyacrylamide/0.1% SDS/8 M urea gels, tropomyosin 
migrated slower than actin (Fig. 1) and a 35 kDa band 
was revealed, corresponding to the molecular mass of 
calponin [5]. This band was observed in all thin filament 
preparations (Fig. 1At. Twelve thin filament prepara- 
tions dating from April 1989 to June 1991 were se- 
parated on urea/SDS gels and the quantity of 35 kDa 
protein was determined by densitometric scans. The 
area of the 35 kDA peak relative to caldesmon was 
0.36+0.1 I. Assuming equal staining per unit mass of 
protein, this corresponds to 0.9 tool calponin per mol 
caldesmon (0.056 35 kDa protein per actin). 
The 35 kDA protein was isolated from sheep aorta 
thin filaments (Fig. I B) and identified as calponin by 
comparison of its apparent molecular mass, its pre- 
cipitation by 30% ammonium sulphate and its amino 
acid composition with the values published by Ta- 
kahashi [3,5]. 
3,2, Calpon#~ #lhibition of actomyosOz A TPase 
Purified calponin inhibited actomyosin MgATPase 
up to 85% both in the presence and absence of tropo- 
myosin (Fig. 2), Half maximal inhibition was obtained 
with 0.2 calponin per actin and maximal inhibition at 
0.4 calponin per actin. These figures are similar to re- 
cently published results from chicken gizzard calde- 
smon [9,11,16]. By comparison, caldesmon was 5-10 
times more potent at inhibiting actomyosin ATPase ac- 
tivity in the presence of tropomyosin (half maximal in- 
Ifibition at 0.02 ealdesmon per actin (Fig. 2)). 
Inhibition by calponin was not dependent on Ca-'* 
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concentration (Fig. 3), nor was inhibition significantly 
reversed by Ca2÷.calmodulin (Figs 3,4). In contrast, cal- 
desmon inhibition was reversed by low concentrations 
of Ca-'+.calmodulin when assayed in 90 mM KC! at 
37°C (Fig. 4, [15,17]. 
3.3. The effect of  calponin on caldesmon fimction 
Calponin had no effect on caldesmon inhibition when 
added at a ratio equivalent o 4 times that found in 
native thin filaments (Fig. 3). Higher calponin concen- 
trations inhibited actomyosin ATPase activity in the 
presence of low caldesmon concentrations a ifcalponin 
were acting independently. The possibility that calponin 
might modulate the reversal ofcaldesmon inhibition by 
Ca-'+.calmodulin (Fig. 4) was investigated at25°C in 50 
mM KCI and at 37°C in 90 mM KCI. Calponin was 
added to actomyosin + caldesmon + Ca2+.calmodulin 
mixtures at ratios up to 0.4 calponin per actin, but no 
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Fig. 2. Inhibition of actomyosin ATPase by calponin and caldcsmon, 
Conditions: 28°C. 50 mM KCI buffer (see section 2), 0.5 mg/ml aorta 
f-actin, 0.125 m~Jml skeletal muscle myosin, in the presence (closed 
symbols) or abscncc (open symbols) or0,l 5 rnglml aorta tropomyosin, 
Circles (.O), calponin', squares (~,11). caldesmon. 
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Fig. 3. Effect of Ca -'+, Ca2+.calmodulin and caldesmon on calponin. 
Conditions: 28°C, 50 mM KCI buffer (see section 2) plus I mM EGTA 
(pCag) or 0.1 mM CaCl,. 0.5 mg/ml aorta ctin, 0.125 mg/ml skeletal 
myosin, 0.15 mg/ml tropomyosin. Calponin was added at 0.2 ealponin 
per actin, caldesmon was added at 0.04 caldesmon per actin and 
calmodulin at 9 pM. Calponin did not influence the 15% reversal of 
caldesmon i hibition due to Ca:'.calmodulin. 
significant change in actomyosin ATPase activity was 
observed (Fig. 3). 
4. DISCUSSION 
4.1. Can calpon#l regulate smooth muscle native thh7 
filame.ts? 
Ca 2÷ has been shown to control the activation of 
smooth or skeletal myosin MgATPase by native thin 
filaments isolated from smooth muscles such as sheep 
aorta [2,6,7,17.19]. These thin filaments contain tropo- 
myosin and caldesmon and in this paper it is shown that 
they also contain calponin approximately equimolar 
with ealdesmon (Fig. 1A). This result is in accord with 
earlier observations on gizzard thin filaments [9]. How- 
ever Takahashi did not find any calponin in thin fila- 
ment preparations unless the ATP concentration was 
greatly reduced. The reason for this discrepancy is not 
clear [10] although Marston and Smith [7] did show that 
thin filament composition was critically dependent on 
the solvent composition and protein concentration dur- 
ing sedimentation. Unlike caldesmon, which is present 
in ratio ofone per 14-16 actins [8], the calponin content 
of thin filament preparations seems to be rather vari- 
able: the average wllue was one per 16 actins, but the 
standard deviation was nearly 30% (.=12) (Fig. IA). 
The maximum reported figure is l per l0 actins [10]. 
The sheep aorta calponin described in this paper is as 
potent an inhibitor of aorta actin + skeletal muscle 
myosin MgATPase (Fig. 2) as any of the gizzard cal- 
ponin preparations previously described [4,9,16,18] 
which were assayed with smooth muscle myosin. Thus 
the myosin type does not seem to significantly influence 
calponin inhibition of actin. Even at a ratio of 1 cal- 
ponin per ten actins no more than 20% inhibition of 
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Fig. 4. Reversal of inhibition by Ca-'+.calmodulin. Conditions: 0.5 
mg/ml aorta actin, 0.125 mg/ml skeletal muscle myosin, 0.12 mglml 
tropomyosin, 0--30//M calmodulin, 0.1 mM CaCI,. Circles, calponin. 
(©) 37°C, 90 mM KCI, 0.2 tool ealponin/mol actin. (e) 29°C. 50 mM 
KCI. 0.26 tool calponin/moi actln. Squares, caldesmon. (D) 37°C. 90 
mM KCI, 0.19 caldesmon/actin. (I) 29°C. 50 mM KCI, 0.06 cal- 
desmon/actin. 
actomyosin ATPase has been observed; this suggests 
that calponin is unlikely to modulate native thin fila- 
ments in vitro. Moreover calponin inhibition shows no 
sign whatsoever of being under the control of  Ca 2+ or 
Ca2+.calmodulin (Figs. 3,4). Phosphorylation has been 
reported to module calponin, but only in the direction 
of making it even less inhibitory [9]. 
In contrast, caldesmon is an effective inhibitor of 
both smooth and skeletal muscle actomyosin ATPase at 
the ratios found in native thin filaments (Fig. 2, [17]) 
and its inhitition may be regulated by C,.a 2÷ and calmo- 
dulin in synthetic filament systems (Fig. 4 [15,17]). In 
addition there is direct evidence that caldesmon is neces- 
sary for the Ca2÷-dependent regulation of smooth mus- 
cle thin filament activation of myosin MgATPase activ- 
ity [19]. 
4.2. Does calpon#l modulate caldesmon-mediated r gu- 
lation? 
It has been noted that the regulatory properties of 
synthetic filaments reconstituted with actin, tropomyo- 
sin, caldesmon and calmodulin (see Fig. 4) are not the 
same at those of native thin filaments. For instance, 
activation of myosin MgATPase by native thin fila- 
ments is Ca2+-dependent at 25°C, whilst activation by 
synthetic thin filaments is not (Fig. 4 [2,15,20-22]). 
Since calponin is equimolar with caldesmon in native 
thin filament preparations it is possible that calponin, 
whilst having no direct regulatory effect, may function 
by modulating caldesmon inhibition and its interaction 
with Ca2*.calmodulin. In fact, calponin, even at ratios 
in excess of those in thin filaments, had no significant 
effect on caldesmon inhibition, nor did it alter the rever- 
sal ofcaldesmon inhibition by Ca2*.calmodulin (Fig. 3). 
There is therefore 11o evidence that calponin is the mo- 
dulator protein which was proposed to be a component 
of native thin filaments [21,23]. 
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4.3. Cellular location of calponin 
Since calponin has a high affinity for actin and will 
also bind to tropomyosin [5,9] it is not surprising that 
thin filaments isolated from smooth muscle homogena- 
tes contain bound calponin, but this does not necessa- 
rily mean that calponin is a component of thin fila- 
ments. Calponin is an extremely basic protein and this 
property alone may be sufficient o account for actin 
binding and inhibiting properties [11]. There is, as yet, 
no direct evidence that calponin co-localises with cal- 
desmon in the actin filaments of the contractile domain 
of smooth muscles. Indeed, in vitro it appears that cal- 
ponin and caldesmon are competitive for actin binding 
[18] whilst Lehman has recently reviewed evidence that 
calponin and caldesmon are segregated into separate 
populations of thin filaments within the cell [24]. In 
recent studies using antibodies to calponin in cultured 
smooth muscle cells, calponin was seen to stain stress 
fibres, primarily in the central portion of the cell, but its 
location was not precisely defined [25,26]. 
A number of papers have made the suggestion that 
calponin might regulate actomyosin ATPase on the 
basis of some of its in vitro properties [4,5,9,10]. How- 
ever if one takes into account he quantity present in 
native thin filament preparations, its weak unregulated 
inhibitory function, its lack of interaction with caldes- 
mon, and the doubt as to whether calponin is located 
in the portion of thin filaments which interact with myo- 
sin, then it is apparent hat the evidence to support a 
regulatory function is lacking. 
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